Abstract
Cryptococcosis is a systemic mycosis caused by two species of the encapsulated basidiomycetes, Cryptococcus neoformans and C. gattii, which, respectively, cause infection in immunocompromised individuals and in immunologically normal hosts. Patients with T-cell deficiencies are more susceptible to this infection. The spectrum of the disease ranges from asymptomatic pulmonary lesions to disseminated infection with meningoencephalitis. The medical relevance of cryptococcosis increased dramatically as a consequence of the AIDS epidemic and organ transplants.

Keywords: Cryptococcus neoformans; Pneumonia; Acquired immunodeficiency syndrome; Amphotericin B; Fluconazole.

Introduction
Cryptococcosis is an infection caused by the naturally encapsulated basidiomycete of the genus Cryptococcus, which has recently become the most relevant opportunistic fungal pathogen. The infection caused by the species C. neoformans has become the most critically relevant opportunistic infection as a consequence of the AIDS epidemic. In addition, C. gattii recently caused an isolated cryptococcosis outbreak among apparently immunocompetent humans and animals on Vancouver Island, Canada.

Cryptococcus spp. are currently divided into five capsular serotypes and eight molecular genotypes. The serotype classification is based on the agglutination reactions of capsular polysaccharide antigens. Serotype A and serotype D strains, as well as the AD hybrid, are classified as C. neoformans, whereas serotype B and serotype C strains have been classified as C. gattii. Serotype A strains have been designated C. neoformans var. grubii, whereas serotype D strains have been designated C. neoformans var. neoformans. This classification was based on the differences in capsular structure and DNA between the strains, as well as on a complete comparison of the genomic sequencing of these two serotypes (strains). In addition, based on new molecular data and on evolutionary studies,
each one of the two species comprises four molecular types: VNI to VNIV (C. neoformans); and VGI to VGIV (C. gattii). The life cycle of Cryptococcus spp. comprises two stages, i.e., sexual and asexual. Cryptococcus neoformans (variants grubii and neoformans) and Cryptococcus gattii are considered to be anamorphic (asexual) strains. The corresponding teleomorphic (sexual) strains are Filobasidiella neoformans and F. bacillispora, respectively.

The virulence of the genus Cryptococcus is associated with the production of oxidases and proteases, as well as with the antipathogenic properties of the capsular polysaccharide. Atypical (non-capsulated) forms present lower pathogenicity. An environment in which there are high concentrations of carbon dioxide favors the bioformation of the capsule.

Cryptococcus spp. present in host tissue as encapsulated yeast (asexual form), which makes them unique among pathogenic fungi. Cryptococcus spp. are observed with or without budding; they are also observed as multi-budding, poorly-encapsulated or capsule-deficient fungal elements or as pseudohyphae.

In the environment, C. neoformans is found in association with pigeon excreta and in tree hollows worldwide. For years, C. gattii was found only in tropical and subtropical regions. C. gattii was primarily associated with eucalypti, which were considered to be its environmental niche. However, the unprecedented emergence of many C. gattii isolates on Vancouver Island shows that the distribution and ecology of C. gattii is changing with its ability to associate itself with a wide variety of trees, such as firs and oaks.

The most theoretically plausible explanation for the infection is the diameter (1.2–1.8 µm) of the fungal propagules (basidiospores), which can accumulate in the alveoli and, at a temperature of 37°C, change into capsulated yeasts. The host develops a primary pulmonary lymph node complex. In most cases, the inhalation of Cryptococcus spp. causes a self-limiting, asymptomatic pulmonary infection, and the yeasts might remain latent within this complex, die or, in the event of subsequent immunosuppression, be reactivated and cause disease. This primary infection can also cause pulmonary symptoms in the host in cases of immunosuppression or of massive inoculation of the yeast. The dissemination from the lungs to other organs can potentially occur as a result of a primary or secondary infection.

In the stage of dissemination from the lungs, the brain is the organ most likely to be the target of that dissemination and to present clinically relevant disease. Therefore, most data refer to manifestations of the disease in the lungs or in the central nervous system (CNS). This tropism for the CNS is attributed to the optimal cerebrospinal fluid (CSF) concentration of nutrients (thiamine, glutamic acid, glutamine, dopamine, carbohydrates and minerals) that can be assimilated by the fungus, to the inactivity of the complement system in the CSF and to the weakness or absence of inflammatory activity in brain tissue.

Before the HIV epidemic, cryptococcosis was an uncommon systemic infection that affected patients with immunosuppression generally associated with the following: use of corticosteroids; diabetes mellitus; Hodgkin’s disease; systemic lupus erythematosus; or other types of immunosuppressive therapy. However, the incidence of cryptococcosis has increased dramatically in the last two decades. More than 80% of the cases of cryptococcosis worldwide have been associated with HIV infection.

In the pre-combined antiretroviral (cARV) therapy era, cryptococcosis became the major opportunistic infection and the major cause of death among HIV-infected patients with CD4 < 100 cells/µl. After the potent cARV therapy became available, the incidence of cryptococcosis decreased significantly; however, the incidence of cryptococcosis in patients who are not infected by HIV has not changed during this period. Although the increase in cARV therapy use is associated with the decrease in the incidence of cryptococcosis in developed countries, the incidence of and mortality from cryptococcosis remains extremely high in countries in which the HIV epidemic is uncontrolled and in which access to drugs and health care is limited. In developed countries, cryptococcosis has not disappeared because the high-risk groups continue to increase, which is due to the advances in transplantation medicine and to the creation of new immunosuppressive therapies. In Brazil, cryptococcosis is a public health issue in patients with AIDS.
Among the cases of cryptococcosis in humans, *C. neoformans* var. *grubii* (serotype A) is the species that is most commonly isolated from clinical samples worldwide.[24] This serotype accounts for more than 95% of the cases of cryptococcosis. *C. neoformans* var. *neoformans* (serotype D, less thermotolerant) commonly causes disease in certain European countries and in the United States.[1] Until recently, *C. gattii* (serotypes B and C) was found to cause cryptococcosis in tropical and subtropical areas such as Australia, southern Asia and Central Africa, as well as in tropical and subtropical areas of the Americas.[25] In Brazil, studies have shown that serotype A is the most prevalent, followed by serotypes B, D and AD.[26]

**Clinical manifestations**

The organs that constitute the CNS and the respiratory tract are the most affected by *C. neoformans* and *C. gattii* infections, although other organs, such as the skin, prostate, eyes, bones and urinary tract, as well as the blood, might be infected.[27,28] In fact, this yeast can cause disease in any organ of the human body, and cryptococcosis can disseminate to multiple organs in severely immunocompromised patients.[29-31]

It was previously believed that the clinical manifestations of *C. neoformans* infection and of *C. gattii* infection were similar. However, evidence has confirmed that the clinical manifestations of *C. neoformans* infection and of *C. gattii* infection can be different.[32,33] *C. gattii*, for instance, causes disease in immunocompetent hosts with large inflammatory masses (cryptococcomas) and commonly produces neurological sequelae that require surgery and long-term antifungal therapy.[33] *C. neoformans*, however, affects immunocompromised patients, causing small pulmonary lesions (seen on X-rays) associated with meningitis (Figure 1), and, due to its proteolytic activity, presents cryptococemia and cryptococcuria, manifestations that are rarely found in *C. gattii* infections.[7]

The presentation of cryptococcosis in HIV-infected patients is somewhat different from that in non-HIV-infected patients.[30] The association between HIV and cryptococcosis causes greater extrapulmonary and CNS involvement and a high rate of positive India ink (nigrosin) test results and of positive blood culture results. In addition, this association results in few inflammatory cells in the CSF. These clinical results suggest that HIV-infected patients present a high concentration of organisms and a minimal inflammatory reaction at the site of infection.

In addition to being the main point of entry for these fungi, the lung is the site that is most commonly affected by cryptococcosis and presents various clinical manifestations that range from asymptomatic infection, such as a solitary nodule, to severe pneumonia.[30] Patients with acute pulmonary cryptococcosis can present fever, productive cough, chest pain and weight loss.[14]

The organs that constitute the CNS are the most commonly affected by *C. neoformans* and *C. gattii*, which can cause acute, subacute or chronic meningitis, as well as severe meningoencephalitis. The signs and symptoms are generally present for various weeks and include headache, fever, cranial neuropathy, altered level of consciousness, lethargy, memory loss, signs of meningeal irritation and coma.[30]

**Radiological diagnosis**

The principal radiological findings are solitary or multiple nodules, subpleural masses and consolidation with air bronchogram. Other findings, less common, include pleural effusion, hilar lymphadenopathy, diffuse reticulonodular opacity and endobronchial lesions resulting in airway obstruction with pulmonary collapse, as well as findings that mimic pulmonary metastases.[1,15,36]
Chapter 3 - Pulmonary cryptococcosis

Isolated pulmonary cryptococcosis (without brain metastasis) or pulmonary cryptococcosis accompanied by brain mass (with brain metastasis) caused by C. gattii can mimic lung cancer clinically and radiologically (Figures 2 and 3). Cases of upper lobe consolidation with atypical presentation of Pancoast syndrome have been described.[48]

Pulmonary manifestations are more common than CNS manifestations in immunocompromised patients with cryptococcosis.[49] In fact, the authors of one study found that more than 90% of HIV/AIDS patients with pulmonary cryptococcosis have previously been diagnosed with CNS cryptococcosis.[1] In contrast, CNS involvement in HIV-negative patients with pulmonary cryptococcosis is less common.[1]

![Figure 2 - Anterior (a) and lateral (b) chest X-rays showing a spherical mass of 5 cm in diameter. Reproduced with permission.][17]

![Figure 3 - Axial CT scan of the brain showing cryptococcoma in the right temporal lobe and multiple nodules throughout the brain parenchyma. Reproduced with permission.][18]

Laboratory diagnosis

**Direct examination**

Direct microscopic examination of the CSF using India ink staining to screen for encapsulated yeasts is a low-cost, widely used test that does not require advanced technology. This technique can be employed immediately after a lumbar puncture to visualize encapsulated yeasts of 5-20 µm in diameter on average. Microscopy has a sensitivity of 30-50% in cases of cryptococcal meningitis in patients without AIDS and a sensitivity of up to 80% in patients with AIDS-related cryptococcal meningitis.[1]

**Histopathological examination**

The histopathological identification of cryptococcosis is achieved through basic histochemical techniques, namely H&E staining and the Grocott-Gomori methenamine-silver stain (GMS) technique, as well as through special histochemical techniques, namely Mayer’s mucicarmine (MM) staining and the Fontana-Masson (FM) staining (Table 1).[40,41]

According to the classification proposed by Schwartz, cryptococcosis is divided into two histological categories, i.e., reactive and minimally reactive, based on the tissue reactions of the host and revealed by H&E staining.[42] The reactive pattern is characterized by a granulomatous inflammatory response composed of histiocytes, multinucleated giant cells and lymphocytic infiltration.[41-46] The yeasts are primarily intracellular (phagocytosis).[41,46] Regions of necrosis are occasionally associated with neutrophilic infiltrates.[42,43,46] Fibrotic nodules—cryptococcomas, considered to be a variant of the reactive pattern—are also found. Fibrotic nodules are formed by surrounding fibrotic tissue and present central areas of necrosis that contain yeasts and a variable number of inflammatory cells (Figure 4).[42,47] According to data from the literature, the variant form is related to infection caused by C. gattii.[48]

The minimally reactive pattern is characterized by minimal or no inflammatory response.[42,43] Numerous spherical microorganisms or oval microorganisms (or a combination of the two) of 2-20 µm in diameter, surrounded by a light halo and arranged extracellularly, are
According to various studies, MM staining (Figure 5) is a specific method for visualizing the mucopolysaccharide capsules of Cryptococcus spp. (8,30,40,42) Through the magenta staining of the capsule, it is possible to distinguish between yeast and other fungi, similar in size and shape. (41)

The FM staining (Figure 5) reveals the melanin present on the fungal cell wall. (30,41) The use of the FM staining is limited to cases in which MM staining results do not suffice to confirm the presence of Cryptococcus spp. Therefore, the FM staining is an alternative for diagnosing cases of infections caused by capsule-deficient organisms morphologically suggestive of Cryptococcus spp. (41)

In some cases, complete destruction of tissue architecture is observed (Figure 5). (40) According to some authors, the minimally reactive inflammatory pattern can be suggestive of poor prognosis. (42,43)

The GMS technique is widely used to screen for fungal elements in tissue sections and in smears. (41) The GMS technique reveals morphological characteristics, such as cell wall and budding, and light perinuclear halos surrounding the microorganisms. Active lesions contain numerous budding fungal structures. Single or multiple buds with narrow bases are common (Figure 5). (40) Uncommon forms, which include pseudohyphae, germ tube-like structures and chains of budding yeasts, are easily identified by the GMS technique. (9,40,49)

Table 1 - Purposes and limitations of the histopathological techniques in the diagnosis of cryptococcosis caused by capsule-deficient Cryptococcus spp.

<table>
<thead>
<tr>
<th>Technique</th>
<th>Purpose</th>
<th>Limitation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;E</td>
<td>Tissue reaction</td>
<td>Does not show fungal structures</td>
</tr>
<tr>
<td>GMS</td>
<td>Staining fungal cell walls</td>
<td>Is a complex procedure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Is expensive</td>
</tr>
<tr>
<td>MM</td>
<td>Staining capsular envelope</td>
<td>Is unable to diagnose capsule-deficient Cryptococcus spp.</td>
</tr>
<tr>
<td>FM</td>
<td>Staining the melanin in fungal cell walls</td>
<td>Is a complex procedure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Is expensive</td>
</tr>
</tbody>
</table>

GMS: Grocott-Gomori methenamine-silver stain; MM: Mayer’s mucicarmine staining; and FM: the Fontana-Masson staining. *Reproduced with permission.* (41)

Figure 4 - Cryptococcoma. Nodule in the pulmonary cortex causing pleural bulging (a). Histological section presenting yeasts with carminophilic capsule inside the cryptococcoma (b). (Technique: Mayer’s mucicarmine staining; magnification, ×10).
The budding index and carminophilic index

The biological activity of Cryptococcus spp. is characterized through a reliable scale developed to determine the budding index (BI) and the carminophilic index (CI) of the yeast.\(^{42,43}\) The BI is calculated through the percentage of microorganisms that exhibit one or more buds, and it is indicative of in vivo replication.\(^{42}\) The CI is calculated by determining the percentage of microorganisms with capsule (stained by the histochemical technique of MM staining) and is indicative of capsular synthesis.\(^{43}\) According to one group of authors, the BI and CI are both higher in the minimally reactive histological pattern than in the reactive pattern.\(^{42}\) Therefore, there is an inverse correlation between high capsular production and a less intense inflammatory response. According to Schwartz, the scale is potentially useful for interpreting the inflammatory response of the host, for prognosis and for biological activity, demonstrating that the granulomatous response is associated with the control of infection.

Differential diagnosis

The histopathological identification of fungal agents is an excellent diagnostic method because the structures are easily detected through histochemical techniques.\(^{14}\) The micromorphological characteristics of Cryptococcus spp. with intact capsule are distinct, and the diagnosis is unique, since the microorganisms are usually associated with a minimal inflammatory response.\(^{14,40}\) In capsule-deficient fungi, the histological characteristics are rather unspecific, being also found in other pathologies of infectious origin.\(^{41}\)

The use of special staining techniques is justified by the fact that Cryptococcus spp., due
to their variable micromorphology, mimic other yeast-like fungi.\[^{51}\] The identification of the capsule through MM staining is the first step to distinguish the yeast from other fungi of similar size and shape.\[^{40,41,53}\] The greatest difficulty lies in identifying capsule-deficient microorganisms because, due to their smaller size, they are mistaken for the following: *Histoplasma capsulatum*; immature spherules of *Coccidioides immitis*; small forms of * Blastomyces dermatitidis and Paracoccidioides brasiliensis; Candida glabrata*; and *Sporothrix schenckii*.\[^{7,51-54}\] In these cases, the special histochemical staining of FM is used, allowing the differential diagnosis between unusual micromorphological forms of *Cryptococcus* spp. and the fungal structures that mimic this type of yeast.\[^{41,51}\]

**Culture**

*C. neoformans* and *C. gattii* grow easily from biological samples smeared onto standard culture media such as Sabouraud dextrose agar, and colonies can be observed after 48-72 h of incubation at 30-35°C under aerobic conditions.

The *Cryptococcus* spp. isolates can be distinguished from *Candida* spp. through a medium enriched with seeds of *Guizotia abyssinica* (Niger seed agar), which contains phenolic substrates and detects the phenoloxidase activity in *Cryptococcus* spp. by forming melanin, therefore staining the colonies brown.

The species can be determined based on the characteristics of the colors on the L-canavanine-glycine-bromothymol blue medium.\[^{55}\]

**Serology**

Tests to detect the capsular polysaccharide antigen of *Cryptococcus* spp. in the serum and CSF have been widely used and are some of the principal serological tests performed in mycology. The tests use latex particles covered with polyclonal antibodies to the cryptococcal capsule. The sensitivity and specificity of latex agglutination tests for cryptococcal antigen range from 93 to 100% and from 93 to 98%, respectively.\[^{56}\]

**Treatment**

Regarding the diagnosis of pulmonary cryptococcosis, it is essential to guarantee that the disease has not disseminated, especially to the CNS, due to the need for a more aggressive treatment strategy if neurocryptococcosis has developed. The choice of antifungal agent depends on the site of infection and on the immunity of the patient. The principal antifungal agents are amphotericin B (0.5-1.0 mg\(\cdot\)kg\(\cdot\)day\(^{-1}\)) and its lipid derivatives, i.e., fluconazole (400 mg/day) and 5-flucytosine (100 mg\(\cdot\)kg\(\cdot\)day\(^{-1}\)) in combination with amphotericin B because resistance to monotherapy is common.\[^5\]

Unfortunately, 5-flucytosine is not available in Brazil.

In cases of mild or moderate isolated pulmonary cryptococcosis, treatment with fluconazole or itraconazole (200-400 mg/day) can be administered for 6-12 months. In case of dissemination to the CNS, itraconazole should not be used because it does not penetrate the CSF efficiently.\[^5\]

Amphotericin B deoxycholate has been successfully used to treat patients with cryptococcal meningitis because it promotes rapid *Cryptococcus* spp. clearance. However, this drug can cause severe nephrotoxicity. The use of liposomal amphotericin B has the advantage of reducing this toxicity.\[^5\]

Treatment varies according to the species of *Cryptococcus*. *C. gattii* requires a higher dose of amphotericin B, longer treatment duration and, more often than not, surgery. Likewise, sequelae are more common, and mortality is higher.

The correct use of antifungal agents significantly decreases mortality; however, long-term continuous therapy is required in order to prevent recurrence.\[^57\]

**Prevention**

**Prevention of infection**

There is no evidence that exposure to pigeon feces is associated with an increased risk of developing cryptococcosis. However, it is advisable to avoid sites contaminated with bird feces.

**Prevention of disease**

The latex test for the presence of cryptococcal antigen in the serum of asymptomatic individuals should not be routinely performed, due to a low probability of diagnosis.\[^57\]

Prospective clinical studies have shown that the use of fluconazole and itraconazole can reduce the frequency of the disease among
patients with AIDS. However, antifungal prophylaxis should not be routinely performed for the following reasons: the mycosis is uncommon; antifungal prophylaxis has little impact on survival; drug interactions can occur; antifungal resistance can develop; and treatment costs are high. However, prophylaxis should be considered for patients with CD4+ T lymphocyte < 50 cells/µL. In these cases, fluconazole (100-200 mg/day) is the drug of choice. Secondary prophylaxis should be maintained until CD4+ T lymphocyte levels remain higher than 200 cells/µL for more than 6 months.

The use of secondary prophylaxis in previously treated, cured patients prevents the recurrence of the infection. Secondary prophylaxis should be maintained until CD4+ T lymphocyte levels remain higher than 200 cells/µL for more than 6 months.

References


About the authors

Cecília Bittencourt Severo

Alexandra Flávia Gazzoni
Postdoctoral Student. Universitat Rovira, Virgili, Spain.

Luiz Carlos Severo
Associate Professor. Department of Internal Medicine of the Universidade Federal do Rio Grande do Sul – UFRGS, Federal University of Rio Grande do Sul – School of Medicine, Porto Alegre, Brazil.